Analyst Ratings for Roivant Sciences (ROIV)
ROIV Rating Summary
ROIV Price Target Summary
- Highest: $19.00 (Truist Securities)
- Lowest: $6.00 (SVB Leerink)
- Average: $12.50
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$12.50 (+46.2%)
* Over Last 12-Mos
Rating Score: 10 / 10
Percentile Rank: 95%
Avg. $ Target:
$12.50 (+46.2%)
* Over Last 12-Mos
Rating Score: 10 / 10
Percentile Rank: 95%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/23/2022 | SVB Leerink | David Risinger | New Coverage | Outperform (N/A) |
6.00 (N/A) |
3.65 (8.55) |
134.25% | Details |
| 4/29/2022 | Cantor Fitzgerald » Updated 9/26/2022 |
Louise Chen | New Coverage | Overweight (N/A) |
15.00 (N/A) |
3.86 (8.55) |
121.5% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
ROIV Ratings News
- RBC Capital on Prometheus Biosciences Inc (RXDX): 'continue to see PRA023 with best-in-class potential in UC'
- Credit Suisse on Prometheus (RXDX): 'Roivant’s Ph2b UC Results Support Anti-TL1A Approach; Prometheus’ PRA023 Maintains Best-in-Class Profile'
- Truist Securities on Roivant Sciences (ROIV): 'RVT-3101 looks competitive in UC with differentiated safety/efficacy profile'
- See More
